Heat shock protein and proteasome targeting agents

Hematology/Oncology Clinics of North America

Volumn 16, Issue 5, 2002, Pages 1269-1285

  Takimoto, Chris H ^a,b   Diggikar, Shrinivas ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 DEMETHOXYGELDANAMYCIN; ANSAMYCIN DERIVATIVE; BENZOQUINONE DERIVATIVE; BORTEZOMIB; DOXORUBICIN; GELDANAMYCIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90; PACLITAXEL; PROTEASOME; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CYSTEINE PROTEINASE; DRUG DERIVATIVE; MACROCYCLIC LACTAM; MULTIENZYME COMPLEX; PROTEINASE INHIBITOR; QUINONE DERIVATIVE; RIFABUTIN; TUMOR PROTEIN; UBIQUITIN;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; FATIGUE; FEVER; HUMAN; HYPOTENSION; LIVER TOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SENSORY NEUROPATHY; STRUCTURE ANALYSIS; THROMBOCYTOPENIA; VOMITING; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG SCREENING; EXPERIMENTAL NEOPLASM; METABOLISM; MOUSE; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHYSIOLOGY; PROTEIN PROCESSING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BENZOQUINONES; CLINICAL TRIALS, PHASE I; CYSTEINE ENDOPEPTIDASES; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MICE; MOLECULAR STRUCTURE; MULTIENZYME COMPLEXES; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; QUINONES; RIFABUTIN; UBIQUITIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036817048     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(02)00048-5     Document Type: Review

References (72)

1. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity. Invest New Drugs 1999;17:361-73.
2. Scheibel T, Buchner J. The Hsp90 complex-a super-chaperone machine as a novel drug target. Biochem Pharmacol 1998;56:675-82.
3. Hickey E, Brandon SE, Smale G, et al. Sequence and regulation of a gene encoding a human 89-kilodalton heat shock protein. Mol Cell Biol 1989;9:2615-26.
4. Richter K, Buchner J. Hsp90: Chaperoning signal transduction. J Cell Physiol 2001;188: 281-90.
5. Ferrarini M, Heltai S, Zocchi MR, et al. Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 1992;51:613-9.
6. Stebbins CE, Russo AA, Schneider C, et al. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell 1997;89:239-50.
7. Scheibel T, Neuhofen S, Weikl T, et al. ATP-binding properties of human Hsp90. J Biol Chem 1997;272:18608-13.
8. Buchner J. Hsp90 & Co. - A holding for folding. Trends Biochem Sci 1999;24:136-41.
9. Pratt WB. The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. Annu Rev Pharmacol Toxicol 1997;37: 297-326.
10. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996; 271:22796-801.
11. Schulte TW, An WG, Neckers LM. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem Biophys Res Commun 1997;239:655-9.
12. Schulte TW, Blagosklonny MV, Ingui C, et al. Disruption of the Rat-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 1995;270: 24585-8.
13. Schulte TW, Blagosklonny MV, Romanova L, et al. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signaling pathway. Mol Cell Biol 1996;16:5839-45.
14. Stancato LF, Silverstein AM, Owens-Grillo JK, et al. The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. J Biol Chem 1997; 272:4013-20.
15. Shao J, Grammatikakis N, Scroggins BT, et al. Hsp90 regulates p50(cdc37) function during the biogenesis of the active conformation of the heme-regulated eIF2 alpha kinase. J Biol Chem 2001;276:206-14.
16. Uehara Y, Fukazawa H, Murakami Y, et al. Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds. Biochem Biophys Res Commun 1989;163:803-9.
17. Uehara Y, Murakami Y, Sugimoto Y, et al. Mechanism of reversion of Rous sarcoma virus transformation by herbimycin A: Reduction of total phosphotyrosine levels due to reduced kinase activity and increased turnover of p60v-src1. Cancer Res 1989;49:780-5.
18. Aligue R, Akhavan-Niak H, Russell P. A role for Hsp90 in cell cycle control: Weel tyrosine kinase activity requires interaction with Hsp90. EMBO J 1994;13:6099-106.
19. Hu J, Seeger C. Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc Natl Acad Sci U S A 1996;93:1060-4.
20. Blagosklonny MV, Toretsky J, Neckers L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 1995;11:933-9.
21. Rutherford SL, Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature 1998; 396:336-42.
22. DeBoer C, Meulman PA, Wnuk RJ, et al. Geldanamycin, a new antibiotic. J Antibiot (Tokyo) 1970;23:442-7.
23. Sasaki K, Rinehart Jr. KL, Slomp G, et al. Geldanamycin. I. Structure assignment. J Am Chem Soc 1970;92:7591-3.
24. Uehara Y, Murakami Y, Suzukake-Tsuchiya K, et al. Effects of herbimycin derivatives on src oncogene function in relation to antitumor activity. J Antibiot (Tokyo) 1988;41:831-4.
25. Supko JG, Hickman RL, Grever MR, et al. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995;36:305-15.
26. Whitesell L, Mimnaugh EG, De Costa B, et al. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994;91:8324-8.
27. Whitesell L, Shifrin SD, Schwab G, et al. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res 1992;52:1721-8.
28. Prodromou C, Roe SM, O'Brien R, et al. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997;90:65-75.
29. Srethapakdi M, Liu F, Tavorath R, et al. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 2000;60:3940-6.
30. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998;42:273-9.
31. Schnur RC, Corman ML, Gallaschun RJ, et al. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 1995; 38:3806-12.
32. Munster PN, Basso A, Solit D, et al. 17-(Allylamino)-17-demethoxygeldanamycin (17-AAG) inhibits intra-cellular Akt kinase activity in HER2 overexpression breast cancer cell lines and enhances the apoptosis induced by cytotoxic agents. Clin Cancer Res 2000;6(Suppl):45455.
33. Nguyen DM, Lorang D, Chen GA, et al. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: In vitro and in vivo analysis. Ann Thorac Surg 2001;72:371-8.
34. Munster PN, Basso A, Solit D, et al. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule- dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res, 7: 2155-2158, 2001. Clin Cancer Res 2001;7:2228-36.
35. Egorin MJ, Zuhowski EG, Rosen DM, et al. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 2001;47:291-302.
36. Egorin MJ, Rosen DM, Wolff JH, et al. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 1998;58: 2385-96.
37. Brunton VG, Steele G, Lewis AD, et al. Geldanamycin-induced cytotoxicity in human coloncancer cell lines: Evidence against the involvement of c-Src or DT-diaphorase. Cancer Chemother Pharmacol 1998;41:417-22.
38. Kelland LR, Sharp SY, Rogers PM, et al. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9.
39. Kelsey KT, Ross D, Traver RD, et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer 1997;76:852-4.
40. Wilson RH, Takimoto CH, Agnew EB, et al. Phase I pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in adult patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001;20:82a.
41. Simon R, Freidlin B, Rubinstein L, et al. Accelerated titration designs for phase 1 clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47.
42. Agnew EB, Wilson RH, Grem JL, et al. Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001;755:237-43.
43. Munster PN, Tong W, Schwartz L, et al. Phase I trial of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) in patients (pts) with advanced solid malignancies. Proc Am Soc Clin Oncol 2001;20:83a.
44. Banerji U, O'Donnell A, Scurr M, et al. Phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino 17-demethoxygeldanamycin (17aag). Pharmacokinetic (PK) profile and pharmacodynamic (PD) endpoints. Proc Am Soc Clin Oncol 2001;20:82a.
45. Erlichman C, Toft D, Reid J, et al. A phase I trial of 17-allyl-amino-geldanamycin in patients with advanced cancer. Proc Am Assoc Cancer Res 2001;42:833.
46. Schulte TW, Akinaga S, Soga S, et al. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 1998;3:100-8.
47. Sharma SV, Agatsuma T, Nakano H. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 1998;16:2639-45.
48. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: A new strategy in cancer treatment. Invest New Drugs 2000;18:109-21.
49. Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001;21:245-73.
50. Shah SA, Potter MW, Callery MP. Ubiquitin proteasome pathway: Implications and advances in cancer therapy. Surg Oncol 2001;10:43-52.
51. Jentsch S. The ubiquitin-conjugation system. Annu Rev Genet 1992;26:179-207.
52. Glickman MH, Rubin DM, Coux O, et al. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. Cell 1998;94:615-23.
53. Kisselev AF, Akopian TN, Woo KM, et al. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J Biol Chem 1999;274:3363-71.
54. Aberle H, Bauer A, Stappert J, et al. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997;16:3797-804.
55. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: Stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 2000;20:2423-35.
56. Salvat C, Jariel-Encontre I, Acquaviva C, et al. Differential directing of c-Fos and c-Jun proteins to the proteasome in serum-stimulated mouse embryo fibroblasts. Oncogene 1998; 17:327-37.
57. Tsurumi C, Ishida N, Tamura T, et al. Degradation of c-Fos by the 26S proteasome is accelerated by c-Jun and multiple protein kinases. Mol Cell Biol 1995;15:5682-7.
58. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B. cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419-28.
59. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
60. Drexler HC. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A 1997;94:855-60.
61. Orlowski RZ, Eswara JR, Lafond-Walker A, et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998; 58:4342-8.
62. Cusack Jr. JC, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001;61:3535-40.
63. Teicher BA, Ara G, Herbst R, et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-45.
64. Mimnaugh EG, Yunmbam MK, Li Q, et al. Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors. Biochem Pharmacol 2000;60:1343-54.
65. Papandreou C, Pagliaro L, Millikan RE, et al. Phase I study of PS-341, a novel proteasome inhibitor in patients with advanced malignancies. Proc Am Soc Clin Oncol 2000;19:738.
66. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11.
67. Hamilton AL, Eder JP, Pavlick CA, et al. PS-341: Phase I study of a novel proteasome inhibitor with pharmacodynamic endpoints. Proc Am Soc Clin Oncol 2001;20:336.
68. Erlichman C, Adjei AA, Thomas JP, et al. A phase I trial of the proteasome inhibitor PS-341 in patients with advanced cancer. Proc Am Soc Clin Oncol 2001;20:337.
69. Nix D, Pien C, Newman R, et al. Clinical development of a proteasome inhibitor, PS-341, for the treatment of cancer. Proc Am Soc Clin Oncol 2001;20:339.
70. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
71. Stinchcombe TE, Mitchell BS, Depcik-Smith N, et al. PS-341 is active in multiple myeloma: Preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies. Proc Am Soc Hematol 2000;96:219.
72. Richardson P, Berenson J, Irwin D, et al. Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy. Proc Am Soc Hematol 2001;98:223.